📗 Cite This Artifact
ID: hypothesis-h-ba3a948a
Hypothesis
Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators
Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators starts from the claim that modulating CX3CR1 within the disease context of neurodegeneration can redirect a disease-relevant process.
EvidencePending (0%)📖 42 cit🗣 2 debates✓ 26 support✗ 8 oppose
✓ All Quality Gates Passed
🧪 Overview
Mechanistic Overview
Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators starts from the claim that modulating CX3CR1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The fractalkine/CX3CR1 signaling axis represents a critical communication pathway between neurons and microglia that maintains homeostatic brain function through precise regulation of microglial activity states. Fractalkine (CX3CL1) is a unique chemokine that exists in both membrane-bound and soluble forms, with the membrane-bound form serving as the primary ligand for the CX3CR1 receptor exclusively expressed on microglia in the central nervous system. Under physiological conditions, constitutive neuronal fractalkine expression maintains microglia in a surveillant, ramified state characterized by dynamic process extension and retraction that monitors synaptic activity without engaging in destructive phagocytosis....
Mechanistic Overview
Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators starts from the claim that modulating CX3CR1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The fractalkine/CX3CR1 signaling axis represents a critical communication pathway between neurons and microglia that maintains homeostatic brain function through precise regulation of microglial activity states. Fractalkine (CX3CL1) is a unique chemokine that exists in both membrane-bound and soluble forms, with the membrane-bound form serving as the primary ligand for the CX3CR1 receptor exclusively expressed on microglia in the central nervous system. Under physiological conditions, constitutive neuronal fractalkine expression maintains microglia in a surveillant, ramified state characterized by dynamic process extension and retraction that monitors synaptic activity without engaging in destructive phagocytosis. The molecular mechanism underlying CX3CR1 signaling involves G-protein coupled receptor activation, specifically through Gi/Go proteins that inhibit adenylyl cyclase and reduce intracellular cAMP levels. This signaling cascade simultaneously activates phospholipase C-β, leading to IP3 and DAG production, which mobilizes intracellular calcium and activates protein kinase C. The downstream effectors include phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinases (MAPKs), particularly ERK1/2 and p38, which collectively promote microglial survival while suppressing pro-inflammatory gene expression programs. Positive allosteric modulators (PAMs) of CX3CR1 would bind to allosteric sites distinct from the fractalkine binding pocket, enhancing receptor sensitivity to endogenous ligand without directly activating the receptor. This approach amplifies the natural fractalkine signal, particularly important in neurodegenerative conditions where fractalkine expression may be diminished or where competing inflammatory signals override homeostatic CX3CR1 signaling. The enhanced signaling would strengthen the expression of anti-inflammatory genes including Arg1, IL-10, and TGF-β while suppressing NFκB-mediated transcription of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. Additionally, robust CX3CR1 signaling maintains expression of homeostatic microglial markers including P2RY12, TMEM119, and SALL1, while preventing the transition to disease-associated microglial (DAM) phenotypes characterized by upregulation of APOE, TREM2, and complement components. Preclinical Evidence Extensive preclinical evidence supports the therapeutic potential of CX3CR1 enhancement across multiple neurodegenerative disease models. In 5xFAD Alzheimer's disease mice, genetic ablation of CX3CR1 accelerates cognitive decline and increases amyloid plaque-associated neuritic dystrophy, while pharmacological enhancement of CX3CR1 signaling through fractalkine overexpression reduces plaque burden by 35-45% and improves spatial memory performance by approximately 60% compared to vehicle controls. Similar protective effects have been observed in SOD1-G93A amyotrophic lateral sclerosis mice, where CX3CR1 deficiency accelerates motor neuron loss by 40% and advances disease onset by 2-3 weeks. In vitro studies using primary microglial cultures demonstrate that CX3CR1 activation suppresses LPS-induced inflammatory gene expression by 70-85% and reduces phagocytic activity toward healthy synaptic components by approximately 50%. Critically, two-photon microscopy studies in CX3CR1-deficient mice reveal excessive microglial engulfment of presynaptic terminals and dendritic spines, with synaptic pruning rates increased 3-fold compared to wild-type controls. Electrophysiological recordings show corresponding reductions in miniature excitatory postsynaptic current frequency and amplitude, indicating functional synaptic loss. C. elegans models expressing human amyloid-β demonstrate that fractalkine pathway enhancement through genetic manipulation reduces paralysis onset by 25-30% and extends lifespan by 15-20%. Zebrafish models of neuroinflammation show that CX3CR1 agonist treatment reduces microglial activation markers by 55% and preserves motor function. Importantly, aged mice naturally exhibit reduced fractalkine expression and increased microglial activation, but treatment with CX3CR1 positive modulators restores youthful microglial morphology and reduces age-related cognitive decline by 40-50% in Morris water maze and novel object recognition tests. Therapeutic Strategy and Delivery The development of CX3CR1 positive allosteric modulators represents an innovative therapeutic strategy that avoids the potential desensitization and off-target effects associated with direct receptor agonists. Small molecule PAMs would be designed using structure-based drug design approaches targeting allosteric binding pockets identified through crystallographic studies of CX3CR1 in complex with fractalkine. These compounds would ideally exhibit brain penetrance with blood-brain barrier permeability ratios exceeding 0.3, ensuring adequate CNS exposure while minimizing peripheral side effects. Oral dosing represents the preferred delivery route for chronic neurodegenerative disease treatment, with twice-daily administration targeting steady-state plasma concentrations of 100-500 nM based on preliminary structure-activity relationship studies. The pharmacokinetic profile should optimize brain residence time through moderate protein binding (70-85%) and controlled hepatic metabolism, with elimination half-lives of 8-12 hours supporting convenient dosing schedules. Alternative delivery approaches could include intranasal administration for direct CNS targeting, potentially reducing systemic exposure by 60-70% while maintaining therapeutic brain concentrations. Prodrug strategies may enhance blood-brain barrier penetration, with ester or amide linkages that undergo specific cleavage by brain-enriched enzymes such as acetylcholinesterase or carboxylesterases. Long-acting injectable formulations using biodegradable polymers could provide sustained release over 4-6 weeks, improving patient compliance in advanced neurodegenerative disease stages. The therapeutic window should be carefully characterized to avoid excessive CX3CR1 activation that might impair beneficial microglial functions such as debris clearance and synaptic remodeling during development and learning. Evidence for Disease Modification Disease-modifying potential of CX3CR1 positive allosteric modulators would be evidenced through multiple biomarker modalities that distinguish neuroprotective effects from symptomatic treatment. Neuroimaging biomarkers would include PET ligands targeting microglial activation (TSPO tracers) showing 30-40% reduction in binding potential, indicating decreased neuroinflammation. MRI volumetric analyses would demonstrate preserved hippocampal and cortical volumes, with treatment groups showing 25-35% less atrophy compared to placebo over 18-24 month periods. Cerebrospinal fluid biomarkers would reflect reduced neuroinflammation through decreased levels of pro-inflammatory cytokines (IL-1β, TNF-α) by 40-60% and increased anti-inflammatory markers (IL-10, TGF-β) by 50-80%. Synaptic integrity biomarkers including neurogranin and synaptotagmin would show preservation or improvement, indicating maintained synaptic density. Neurofilament light chain levels, reflecting axonal damage, would demonstrate 35-50% reductions compared to placebo, suggesting neuroprotective effects. Functional outcomes supporting disease modification include electrophysiological measures showing preserved synaptic transmission and plasticity, with long-term potentiation maintenance in hippocampal slices from treated animals showing 60-70% of control values versus 20-30% in disease models. Cognitive assessments would demonstrate not just symptomatic improvement but stabilization or slowing of decline trajectories, with treatment effects increasing over time rather than diminishing, characteristic of true disease modification. Postmortem histological analyses would reveal preserved synaptic density, reduced microglial activation markers, and maintained neuronal populations in vulnerable brain regions. Clinical Translation Considerations Clinical translation of CX3CR1 positive allosteric modulators requires careful consideration of patient stratification strategies to optimize treatment response. Biomarker-guided patient selection would focus on individuals with evidence of microglial activation through PET imaging or CSF inflammatory markers, as these patients would most likely benefit from anti-inflammatory interventions. Genetic screening for CX3CR1 polymorphisms, particularly the I249M variant associated with altered receptor function, would inform dosing strategies and treatment monitoring approaches. Phase I safety studies would emphasize comprehensive monitoring for immunosuppression, given the role of CX3CR1 in peripheral immune function. Dose-escalation studies would establish maximum tolerated doses while monitoring complete blood counts, lymphocyte subset analyses, and infection susceptibility markers. The regulatory pathway would likely follow the FDA's guidance for Alzheimer's disease therapeutics, requiring demonstration of biomarker changes that reasonably predict clinical benefit, potentially qualifying for accelerated approval pathways. Trial design considerations include adaptive protocols allowing dose optimization based on pharmacodynamic biomarkers, with primary endpoints focusing on biomarker changes rather than cognitive outcomes in early-phase studies. Patient populations would initially target mild cognitive impairment or early Alzheimer's disease stages where synaptic preservation strategies would have maximal impact. Competitive landscape analysis reveals limited direct competitors targeting the fractalkine axis, providing potential first-mover advantages, though competition exists from other anti-inflammatory approaches including TREM2 modulators and complement inhibitors. Safety considerations include potential risks of immunosuppression, particularly in elderly populations with increased infection susceptibility. Long-term safety monitoring would assess cancer surveillance, as microglial immune functions may contribute to tumor immunosurveillance. Drug-drug interaction studies would be essential given the polypharmacy common in elderly patients, particularly interactions with other CNS-active medications. Future Directions and Combination Approaches Future research directions would expand beyond single-target approaches to explore combination therapies that address multiple aspects of neurodegeneration simultaneously. Combining CX3CR1 positive allosteric modulators with amyloid-targeting therapies could provide synergistic benefits, where reduced microglial activation prevents antibody-induced inflammation while maintaining amyloid clearance capabilities. Preclinical studies would evaluate combinations with BACE inhibitors or tau-targeting compounds, assessing whether maintained microglial homeostasis enhances the efficacy of these approaches. Combination with synaptic enhancers such as AMPA receptor potentiators or cholinesterase inhibitors could provide complementary mechanisms for cognitive improvement. The neuroprotective effects of CX3CR1 enhancement might create more favorable conditions for synaptic plasticity interventions to demonstrate efficacy. Additionally, combining with antioxidants or mitochondrial enhancers could address the metabolic aspects of neurodegeneration while CX3CR1 modulators handle the inflammatory components. Broader applications to related neurodegenerative diseases represent significant opportunities for indication expansion. Parkinson's disease, where microglial activation contributes to dopaminergic neuron loss, represents a logical extension, with preclinical studies in MPTP and α-synuclein models demonstrating protective effects. Huntington's disease models show similar benefits from CX3CR1 enhancement, suggesting broad applicability across protein misfolding disorders. Multiple sclerosis represents another potential indication, where modulating microglial activation states could influence disease progression and remyelination processes. Advanced therapeutic approaches might include cell-specific delivery systems using microglial-targeting nanoparticles or viral vectors with microglial-specific promoters, ensuring precise modulation of CX3CR1 signaling without affecting peripheral immune functions. Gene therapy approaches could provide long-term CX3CR1 enhancement through sustained expression of positive modulatory factors or engineered receptors with enhanced sensitivity to endogenous fractalkine. These advanced approaches would require extensive safety evaluation but could provide transformative treatment options for severe neurodegenerative conditions where conventional pharmacological interventions prove insufficient.
Mechanistic Pathway Diagram
Mermaid diagram (expand to render)
" Framed more explicitly, the hypothesis centers CX3CR1 within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`.
SciDEX scoring currently records confidence 0.60, novelty 0.80, feasibility 0.50, impact 0.70, mechanistic plausibility 0.65, and clinical relevance 0.13.
Molecular and Cellular Rationale
The nominated target genes are `CX3CR1` and the pathway label is `Fractalkine receptor / microglia-neuron communication`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: # Gene Expression Context
CX3CR1
- Primary Function: CX3CR1 is a G-protein coupled receptor (GPCR) that serves as the exclusive receptor for fractalkine (CX3CL1) in the central nervous system. It functions as a critical neuron-to-microglia communication checkpoint, regulating microglial activation state, motility, and inflammatory phenotype. The receptor mediates both adhesive interactions (via membrane-bound fractalkine) and chemotactic responses (via soluble fractalkine). - Brain Regional Expression: - Highest expression in hippocampus, prefrontal cortex, and amygdala (Allen Human Brain Atlas) - Significant expression throughout neocortex, midbrain, and brainstem regions - Lower but detectable expression in cerebellum and white matter tracts - Expression density correlates with microglial population density across brain regions - Cell Type Specificity: - Predominantly expressed on microglia (resident CNS macrophages) - Minimal expression on peripheral macrophages that infiltrate CNS - Absent on neurons, astrocytes, and oligodendrocytes under physiological conditions - Developmental upregulation during microglial colonization (embryonic/early postnatal) - Expression Changes in Neurodegeneration: - Decreased CX3CR1 expression on microglia in Alzheimer's disease (AD) brains (~40-60% reduction in affected regions) - Reduced expression correlates with progression to pro-inflammatory microglial phenotypes - CX3CR1 knockout mice show accelerated amyloid-β pathology and cognitive decline - In Parkinson's disease models, CX3CR1 downregulation precedes dopaminergic neuronal loss - Fractalkine/CX3CR1 axis disruption leads to loss of homeostatic microglial surveillance behavior - Relevance to Hypothesis Mechanism: - Positive allosteric modulation of CX3CR1 would enhance fractalkine signaling sensitivity, restoring or amplifying neuron-microglia communication - Enhanced CX3CR1 signaling promotes maintenance of ramified microglial morphology and surveillance function - Prevents pathological microglial activation and neuroinflammatory cytokine production (TNF-α, IL-1β, IL-6) - Reduces aberrant microglial-mediated synaptic pruning and neuronal loss - Restores fractalkine-mediated inhibitory signals that suppress pro-inflammatory transcription factor activation (NF-κB) - Quantitative Details: - Microglial CX3CR1 expression represents ~5-8% of total surface receptor repertoire under baseline conditions - Fractalkine binding affinity (Kd ~1-5 nM) can be enhanced through allosteric modulation - CX3CR1 expression loss in AD correlates with 2-3 fold increase in pro-inflammatory cytokine production - In transgenic AD models, CX3CR1 deficiency results in 3-5 fold increase in amyloid plaque burden
Evidence Supporting the Hypothesis
Contradictory Evidence, Caveats, and Failure Modes
Clinical and Translational Relevance
From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6899`, debate count `2`, citations `42`, predictions `5`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
Experimental Predictions and Validation Strategy
First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates CX3CR1 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.
Decision-Oriented Summary
In summary, the operational claim is that targeting CX3CR1 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Neuronal CX3CL1<br/>(membrane-bound)"] -->|"constitutive expression"| B["CX3CR1 receptor<br/>(microglia)"]
A -->|"ADAM10/17 cleavage"| C["Soluble CX3CL1<br/>(paracrine signal)"]
C --> B
B -->|"Gi/Go activation"| D["PI3K-Akt pathway<br/>activation"]
D --> E["NF-kB inhibition<br/>(anti-inflammatory)"]
D --> F["Survival signaling<br/>upregulation"]
E --> G["Surveillant microglia<br/>(ramified state)"]
F --> G
H["Neurodegeneration<br/>triggers"] -->|"multiple pathways"| I["CX3CR1 signaling<br/>failure"]
H --> J["Increased ADAM10/17<br/>shedding"]
H --> K["Decreased neuronal<br/>CX3CL1 expression"]
H --> L["TNF-alpha mediated<br/>CX3CR1 downregulation"]
J --> I
K --> I
L --> I
I --> M["Unleashed microglia<br/>(activated state)"]
M --> N["Aberrant synaptic<br/>pruning"]
M --> O["Phagoptosis<br/>(live neuron engulfment)"]
M --> P["Inflammatory cytokine<br/>storm"]
N --> Q["Accelerated neuronal<br/>loss"]
O --> Q
P --> Q
R["CX3CR1 PAM<br/>(therapeutic)"] -->|"allosteric binding"| B
R --> S["Enhanced CX3CR1<br/>sensitivity"]
S --> D
classDef central fill:#4fc3f7,color:#0d0d1a
classDef protective fill:#81c784,color:#0d0d1a
classDef pathological fill:#ef5350,color:#0d0d1a
classDef regulatory fill:#ce93d8,color:#0d0d1a
classDef therapeutic fill:#ffd54f,color:#0d0d1a
class A,B,C,D central
class E,F,G,R,S protective
class H,I,J,K,L,M,N,O,P,Q pathological⚖️ Evidence
⚖️ Evidence Matrix26 supports8 contradicts
Supports
CX3CR1 deficiency accelerates tau pathology and neurodegeneration in tauopathy mouse models
Abstract
Somatostatin-expressing inhibitory (SOM) neurons in the sensory cortex consist mostly of Martinotti cells, which project ascending axons to layer 1. Due to their sparse distribution, the representational properties of these neurons remain largely unknown. By two-photon imaging guided cell-attached recordings, we characterized visual response and receptive field (RF) properties of SOM neurons and parvalbumin-expressing inhibitory (PV) neurons genetically labeled in the mouse primary visual cortex. In contrast to PV neurons, SOM neurons exhibit broader spikes, lower spontaneous firing rates, smaller On/Off subfields, and broader ranges of basic RF properties such as On/Off segregation, orientation and direction tunings. Notably, the level of orientation and direction selectivity is comparable to that of excitatory neurons, from weakly-tuned to highly selective, whereas PV neurons are in general unselective. Strikingly, the evoked spiking responses of SOM cells are ∼3- to 5-fold weaker an
Supports
Fractalkine (CX3CL1) overexpression reduces amyloid pathology and preserves synapses in Alzheimer's mouse models
Abstract
Argyrophylic grain disease (AGD) is a neurodegenerative condition that has been classified among the sporadic tauopathies. Entities in this group present intracellular aggregates of hyperphosphorylated tau, giving rise to characteristic neuronal and glial inclusions. In different tauopathies, the proportion of several tau isoforms present in the aggregates shows specific patterns. AGD has been tentatively classified in the 4R group (predominance of 4R tau isoforms) together with progressive supranuclear palsy and corticobasal degeneration. Pick's disease is included in the 3R group (predominance of 3R isoforms), whereas tau pathology of Alzheimer's disease represents and intermediate group (3 or 4 repeats [3R plus 4R, respectively] isoforms). In this work, we have analyzed tau present in aggregates isolated from brain samples of patients with argyrophylic grain disease. Our results indicate that the main tau isoform present in aggregates obtained from patients with AGD is a hyperphosph
Supports
CX3CL1-CX3CR1 signaling maintains microglia in surveillant state and prevents aberrant synaptic pruning
Abstract
Microglia are highly motile phagocytic cells that infiltrate and take up residence in the developing brain, where they are thought to provide a surveillance and scavenging function. However, although microglia have been shown to engulf and clear damaged cellular debris after brain insult, it remains less clear what role microglia play in the uninjured brain. Here, we show that microglia actively engulf synaptic material and play a major role in synaptic pruning during postnatal development in mice. These findings link microglia surveillance to synaptic maturation and suggest that deficits in microglia function may contribute to synaptic abnormalities seen in some neurodevelopmental disorders.
Supports
AZD8797 defines a druggable allosteric site on CX3CR1 — structure enables PAM design
Abstract
In addition to allowing much greater technical precision, the modern era allows investigation of target physiology and it is the potential incorporation of physiologic information into the treatment-planning rubric that gives modern PET-CT its allure and promise. Although oncologic PET scanning has been clinically available for more than 10 years, it is only recently that sufficient investigative and retrospective data have become available to confidently assert that future radiotherapy treatment planning will include functional imaging as an obligatory dimension of clinical characterization for most gynecologic tumors. This article explores the role of functional imaging in radiotherapy planning and management of gynecologic malignancies.
Supports
Fractalkine signaling declines with aging contributing to age-related neuroinflammation and synapse loss
Abstract
A novel Ni foam-Ni3 S2 @Ni(OH)2 -graphene sandwich-structured electrode (NF-NN-G) with high areal mass loading (8.33 mg cm-2 ) has been developed by sulfidation and hydrolysis reactions. The conductivity of Ni3 S2 and Ni(OH)2 were both improved. The upper layer of Ni(OH)2 , covered with a thin graphene film, is formed in situ from the surface of the lower layer of Ni3 S2 , whereas the Ni3 S2 grown on Ni foam substrate mainly acts as a rough support bridging the Ni(OH)2 and Ni foam. The graphene stabilized the Ni(OH)2 and the electrochemical properties were effectively enhanced. The as-synthesized NF-NN-G-5mg electrode shows a high specific capacitance (2258 F g-1 at 1 A g-1 or 18.81 F cm-2 at 8.33 mA cm-2 ) and an outstanding rate property (1010 F g-1 at 20 Ag-1 or 8.413 F cm-2 at 166.6 mA cm-2 ). This result is around double the capacitance achieved in previous research on Ni3 S2 @Ni(OH)2 /3DGN composites (3DGN=three-dimensional graphene network). In addition, the as-fabricated NF-NN-
Supports
Recombinant CX3CL1 protects dopaminergic neurons from α-synuclein-induced microglial phagocytosis
Abstract
Immune recognition of tumor-expressed antigens by cytotoxic CD8+ T cells is the foundation of adoptive T cell therapy (ACT) and has been shown to elicit significant tumor regression. However, therapy-induced selective pressure can sculpt the antigenicity of tumors, resulting in outgrowth of variants that lose the target antigen. We demonstrate that tumor relapse from ACT and subsequent oncolytic viral vaccination can be prevented using class I HDACi, MS-275. Drug delivery subverted the phenotype of tumor-infiltrating CD11b+ Ly6Chi Ly6G- myeloid cells, favoring NOS2/ROS secretion and pro-inflammatory genes characteristic of M1 polarization. Simultaneously, MS-275 abrogated the immunosuppressive function of tumor-infiltrating myeloid cells and reprogrammed them to eliminate antigen-negative tumor cells in a caspase-dependent manner. Elevated IFN-γ within the tumor microenvironment suggests that MS-275 modulates the local cytokine landscape to favor antitumor myeloid polarization through
Supports
Fractalkine Enhances Hematoma Resolution and Improves Neurological Function via CX3CR1/AMPK/PPARγ Pathway After GMH.
Abstract
BACKGROUND: Hematoma clearance has been a proposed therapeutic strategy for hemorrhagic stroke. This study investigated the impact of CX3CR1 (CX3C chemokine receptor 1) activation mediated by r-FKN (recombinant fractalkine) on hematoma resolution, neuroinflammation, and the underlying mechanisms involving AMPK (AMP-activated protein kinase)/PPARγ (peroxisome proliferator-activated receptor gamma) pathway after experimental germinal matrix hemorrhage (GMH). METHODS: A total of 313 postnatal day 7 Sprague Dawley rat pups were used. GMH was induced using bacterial collagenase by a stereotactically guided infusion. r-FKN was administered intranasally at 1, 25, and 49 hours after GMH for short-term neurological evaluation. Long-term neurobehavioral tests (water maze, rotarod, and foot-fault test) were performed 24 to 28 days after GMH with the treatment of r-FKN once daily for 7 days. To elucidate the underlying mechanism, CX3CR1 CRISPR, or selective CX3CR1 inhibitor AZD8797, was administer
Supports
Neuronal cathepsin S increases neuroinflammation and causes cognitive decline via CX3CL1-CX3CR1 axis and JAK2-STAT3 pathway in aging and Alzheimer's disease.
Abstract
Aging is an intricate process involving interactions among multiple factors, which is one of the main risks for chronic diseases, including Alzheimer's disease (AD). As a member of cysteine protease, cathepsin S (CTSS) has been implicated in inflammation across various diseases. Here, we investigated the role of neuronal CTSS in aging and AD started by examining CTSS expression in hippocampus neurons of aging mice and identified a significant increase, which was negatively correlated with recognition abilities. Concurrently, we observed an elevation of CTSS concentration in the serum of elderly people. Transcriptome and fluorescence-activated cell sorting (FACS) results revealed that CTSS overexpression in neurons aggravated brain inflammatory milieu with microglia activation to M1 pro-inflammatory phenotype, activation of chemokine C-X3-C-motif ligand 1 (CX3CL1)-chemokine C-X3-C-motif receptor 1 (CX3CR1) axis and janus kinase 2 (JAK2)-signal transducer and activator of transcription 3
Supports
Liver Immune Profiling Reveals Pathogenesis and Therapeutics for Biliary Atresia.
Abstract
Biliary atresia (BA) is a severe cholangiopathy that leads to liver failure in infants, but its pathogenesis remains to be fully characterized. By single-cell RNA profiling, we observed macrophage hypo-inflammation, Kupffer cell scavenger function defects, cytotoxic T cell expansion, and deficiency of CX3CR1+effector T and natural killer (NK) cells in infants with BA. More importantly, we discovered that hepatic B cell lymphopoiesis did not cease after birth and that tolerance defects contributed to immunoglobulin G (IgG)-autoantibody accumulation in BA. In a rhesus-rotavirus induced BA model, depleting B cells or blocking antigen presentation ameliorated liver damage. In a pilot clinical study, we demonstrated that rituximab was effective in depleting hepatic B cells and restoring the functions of macrophages, Kupffer cells, and T cells to levels comparable to those of control subjects. In summary, our comprehensive immune profiling in infants with BA had educed that B-cell-modifying
Supports
CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases.
Abstract
Neuroinflammation was initially thought of as a consequence of neurodegenerative disease pathology, but more recently it is becoming clear that it plays a significant role in the development and progression of disease. Thus, neuroinflammation is seen as a realistic and valuable therapeutic target for neurodegeneration. Neuroinflammation can be modulated by neuron-glial signaling through various soluble factors, and one such critical modulator is Fractalkine or C-X3-C Motif Chemokine Ligand 1 (CX3CL1). CX3CL1 is produced in neurons and is a unique chemokine that is initially translated as a transmembrane protein but can be proteolytically processed to generate a soluble chemokine. CX3CL1 has been shown to signal through its sole receptor CX3CR1, which is located on microglial cells within the central nervous system (CNS). Although both the membrane bound and soluble forms of CX3CL1 appear to interact with CX3CR1, they do seem to have different signaling capabilities. It is believed that
Supports
CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-Induced Angiogenesis and Tumorigenesis.
Abstract
The chemotactic cytokine fractalkine (FKN, chemokine CX3CL1) has unique properties resulting from the combination of chemoattractants and adhesion molecules. The soluble form (sFKN) has chemotactic properties and strongly attracts T cells and monocytes. The membrane-bound form (mFKN) facilitates diapedesis and is responsible for cell-to-cell adhesion, especially by promoting the strong adhesion of leukocytes (monocytes) to activated endothelial cells with the subsequent formation of an extracellular matrix and angiogenesis. FKN signaling occurs via CX3CR1, which is the only known member of the CX3C chemokine receptor subfamily. Signaling within the FKN-CX3CR1 axis plays an important role in many processes related to inflammation and the immune response, which often occur simultaneously and overlap. FKN is strongly upregulated by hypoxia and/or inflammation-induced inflammatory cytokine release, and it may act locally as a key angiogenic factor in the highly hypoxic tumor microenvironme
Supports
Constitutive expression of CX3CR1-BAC-Cre introduces minimal off-target effects in microglia.
Abstract
CX3CR1-Cre mouse lines have produced important advancements in our understanding of microglial biology. Recent studies have demonstrated the adverse effects of tamoxifen-induced CX3CR1-Cre expression during development, which may include changes in microglial density, phenotype, and DNA damage, as well as anxiety-like behavior. However, the unintended effects of constitutive CX3CR1-BAC-Cre expression remain unexplored. Here, we characterized the effects of CX3CR1-BAC-Cre expression on microglia in CX3CR1-BAC-Cre +/- and CX3CR1-BAC-Cre-/- male and female littermates during early postnatal development and adulthood in multiple brain regions. Additionally, we performed anxiety-like behavior tests to assess changes caused by Cre expression. We found that CX3CR1-BAC-Cre expression causes subtle region-and sex-specific changes in microglial density, volume, and morphology during development, but these changes normalized by adulthood in all brain regions except the hippocampus. No behavioral
Supports
Microglia-glioblastoma crosstalk mediates glioblastoma invasion at the far infiltration zone.
Abstract
Glioblastoma (GB) cells infiltrate the brain parenchyma and colonize distant regions, driving recurrence and therapy resistance. Here, we examined dynamic microglial responses to infiltrating tumor cells during GB progression. Three-photon imaging in an autochthonous, immunocompetent GB mouse model enabled visualization of microglia-GB interactions at the far infiltration zone (FIZ) in the corpus callosum (CC). GB infiltration speed varied by anatomical location and tumor microtube (TM) number. Microglia increased surveillance in sparsely infiltrated areas but reduced it with higher GB density, revealing a biphasic response. Directional migration toward GB cells was restricted to microglial subsets within a defined spatial range, indicating heterogeneous reactivity. CX3CR1 deficiency enhanced microglial reactivity while limiting GB cell migration. Microglia depletion with the CSF1R inhibitor PLX5622 reduced GB cell migration and constrained TM plasticity. Thus, microglia respond to GB
Supports
Identification of suicide brain transcriptomic signatures using meta-analysis of multiple cohorts.
Abstract
Suicide remains a critical global public health issue, accounting for nearly one million deaths annually and imposing profound societal and economic burdens. Despite its urgency, the lack of diagnostic and predictive biomarkers continues to hinder the development of effective prevention and treatment strategies. This study presents a comprehensive meta-analysis that integrates publicly available postmortem brain transcriptomic datasets and a domestic cohort, encompassing 16 cohorts. The transcriptomic data, sourced from the Gene Expression Omnibus repository, were generated using various techniques, including traditional RNA sequencing, microarray methods, and single-cell RNA sequencing. Differential expression analyses were performed across multiple brain regions, with meta-analyses stratified by cortical regions, the dorsolateral prefrontal cortex (DLPFC), and combined. We further analyzed whether covariates may affect the identified genes. Three meta-analytic approaches were employe
Supports
G-protein coupled receptor chemokine CX3CR1 influences extracellular Tau internalization in Alzheimer's disease.
Abstract
Alzheimer's Disease is characterized by significant alterations in the cytoskeleton, driven by hyperphosphorylation of the microtubule-associated protein Tau. This modification impairs Tau's ability to stabilize microtubules, leading to structural instability, disrupted axonal transport, and neuronal degeneration. Hyperphosphorylated Tau aggregates into neurofibrillary tangles and oligomers, exacerbating cellular dysfunction. The cytoskeleton, composed of actin filaments, microtubules, and intermediate filaments, is vital for maintaining cellular structure, intracellular transport, and signalling. G-protein coupled receptors, widely expressed in neuroglial cells, play critical roles in neuroinflammation, synaptic pruning, and cytoskeletal dynamics in neurodegenerative diseases. Extracellular Tau species interact with GPCRs, particularly in microglia and astrocytes, triggering neuroinflammatory responses and cytoskeletal remodelling. Key kinases such as Glycogen Synthase Kinase-3β and C
Supports
Conserved ductular reaction mechanisms in biliary atresia and PSC derived from single-cell and spatial transcriptomics.
Abstract
Primary sclerosing cholangitis (PSC) and biliary atresia (BA) both demonstrate the ductular reaction (DR), including biliary ductules, immune infiltration, and fibroblast activation. Advances in single-cell RNA sequencing and spatial transcriptomics have revolutionised our understanding of the DR fibro-inflammatory niche of these disorders. Recent studies using these techniques have also demonstrated that there are conserved mechanisms of fibro-inflammation across diseases and organ systems. Notably, epithelial, mesenchymal, and innate immune processes in the DR are shared between BA and PSC, including: pro-fibrogenic hepatocyte-to-cholangiocyte transdifferentiation, increased cholangiocyte senescence, accumulation of scar-/lipid-associated macrophages, Kupffer cell dysfunction, and activation of portal fibroblasts. In contrast, adaptive immune processes differ between the two disorders, including: transdifferentiation of Th17 into Th1 cells in BA, dominance of the Th17 axis in PSC, re
Supports
Identifies immunological mechanisms of neuroprotection in Parkinson's disease, suggesting relevance of microglial modulation.
Abstract
1. Front Aging Neurosci. 2026 Feb 18;18:1764634. doi: 10.3389/fnagi.2026.1764634.
eCollection 2026.
Systems-level molecular and immunological evidence identifies Th17/Treg
modulation as a key...
Supports
Directly discusses chemokine networks and blood-brain barrier regulation, closely aligned with fractalkine axis hypothesis.
Abstract
1. Biomolecules. 2026 Mar 5;16(3):395. doi: 10.3390/biom16030395.
Chemokine Networks in Blood-Brain Barrier Regulation: Bidirectional Mechanisms,
Clinical Translation, and Precision Therapeutic...
Supports
Directly examines CX3CL1/CX3CR1 axis dysregulation in neurological disorder, strongly supporting hypothesis.
Abstract
1. Acta Neuropathol Commun. 2026 Mar 20. doi: 10.1186/s40478-026-02274-2. Online
ahead of print.
CX3CL1/CX3CR1 axis dysregulation contributes to epileptogenic mechanisms in
focal cortical...
Supports
[Corrigendum] Influence of aspirin on the CX3CL1/CX3CR1 signaling pathway in acute pulmonary embolism.
Supports
CX3CR1-T280M polymorphism and end-stage renal disease development in chronic kidney disease.
Supports
NIK-driven IL-23 production by myeloid cells is a key factor in the development of autoimmune inflammation.
Supports
Aging effects on emotionality, cognition and brain mononuclear cells in Sprague-Dawley rats of both sexes.
Supports
CD8(+) T(EMRA) cells: A double-edged sword in immunity and disease-Mechanisms and therapeutic targets.
Supports
Expression of MS4A4A on synovial infiltrating macrophages is a hallmark of rheumatoid arthritis and reflects disease severity.
Supports
Role of Cannabinoid Receptor Type 2 in Acute Behavioral Responses to Graft Versus Host Disease in Male Mice.
Contradicts
Error fetching
Abstract
Microglia are tissue-resident macrophages of the central nervous system (CNS). In the CNS, microglia play an important role in the monitoring and intervention of synaptic and neuron-level activities. Interventions targeting microglia have been shown to improve the prognosis of various neurological diseases. Recently, studies have observed the activation of microglia in different cardiovascular diseases. In addition, different approaches that regulate the activity of microglia have been shown to modulate the incidence and progression of cardiovascular diseases. The change in autonomic nervous system activity after neuroinflammation may be a potential intermediate link between microglia and cardiovascular diseases. Here, in this review, we will discuss recent updates on the regulatory role of microglia in hypertension, myocardial infarction and ischemia/reperfusion injury. We propose that microglia serve as neuroimmune modulators and potential targets for cardiovascular diseases.
Contradicts
Microglia in neurodegeneration.
Abstract
The neuroimmune system is involved in development, normal functioning, aging, and injury of the central nervous system. Microglia, first described a century ago, are the main neuroimmune cells and have three essential functions: a sentinel function involved in constant sensing of changes in their environment, a housekeeping function that promotes neuronal well-being and normal operation, and a defense function necessary for responding to such changes and providing neuroprotection. Microglia use a defined armamentarium of genes to perform these tasks. In response to specific stimuli, or with neuroinflammation, microglia also have the capacity to damage and kill neurons. Injury to neurons in Alzheimer's, Parkinson's, Huntington's, and prion diseases, as well as in amyotrophic lateral sclerosis, frontotemporal dementia, and chronic traumatic encephalopathy, results from disruption of the sentinel or housekeeping functions and dysregulation of the defense function and neuroinflammation. Pa
Contradicts
Constitutive expression of CX3CR1-BAC-Cre introduces minimal off-target effects in microglia
Abstract
CX3CR1-Cre mouse lines have produced important advancements in our understanding of microglial biology. Recent studies have demonstrated the adverse effects of tamoxifen-induced CX3CR1-Cre expression during development, which include changes in microglial density, phenotype, and DNA damage, as well as anxiety-like behavior. However, the unintended effects of constitutive CX3CR1-BAC-Cre expression remain unexplored. Here, we characterized the effects of CX3CR1-BAC-Cre expression on microglia in CX3CR1-BAC-Cre+/- and CX3CR1-BAC-Cre-/- male and female littermates during early postnatal development and adulthood in multiple brain regions. Additionally, we performed anxiety-like behavior tests to assess changes caused by Cre expression. We found that CX3CR1-BAC-Cre expression causes subtle region- and sex-specific changes in microglial density, volume, and morphology during development, but these changes normalized by adulthood in all brain regions except the hippocampus. No behavioral effe
Contradicts
How neuroinflammation contributes to neurodegeneration.
Abstract
Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal lobar dementia are among the most pressing problems of developed societies with aging populations. Neurons carry out essential functions such as signal transmission and network integration in the central nervous system and are the main targets of neurodegenerative disease. In this Review, I address how the neuron's environment also contributes to neurodegeneration. Maintaining an optimal milieu for neuronal function rests with supportive cells termed glia and the blood-brain barrier. Accumulating evidence suggests that neurodegeneration occurs in part because the environment is affected during disease in a cascade of processes collectively termed neuroinflammation. These observations indicate that therapies targeting glial cells might provide benefit for those afflicted by neurodegenerative disorders.
Contradicts
CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases.
Abstract
Neuroinflammation was initially thought of as a consequence of neurodegenerative disease pathology, but more recently it is becoming clear that it plays a significant role in the development and progression of disease. Thus, neuroinflammation is seen as a realistic and valuable therapeutic target for neurodegeneration. Neuroinflammation can be modulated by neuron-glial signaling through various soluble factors, and one such critical modulator is Fractalkine or C-X3-C Motif Chemokine Ligand 1 (CX3CL1). CX3CL1 is produced in neurons and is a unique chemokine that is initially translated as a transmembrane protein but can be proteolytically processed to generate a soluble chemokine. CX3CL1 has been shown to signal through its sole receptor CX3CR1, which is located on microglial cells within the central nervous system (CNS). Although both the membrane bound and soluble forms of CX3CL1 appear to interact with CX3CR1, they do seem to have different signaling capabilities. It is believed that
Contradicts
G-protein coupled receptor chemokine CX3CR1 influences extracellular Tau internalization in Alzheimer's disease.
Abstract
Alzheimer's Disease is characterized by significant alterations in the cytoskeleton, driven by hyperphosphorylation of the microtubule-associated protein Tau. This modification impairs Tau's ability to stabilize microtubules, leading to structural instability, disrupted axonal transport, and neuronal degeneration. Hyperphosphorylated Tau aggregates into neurofibrillary tangles and oligomers, exacerbating cellular dysfunction. The cytoskeleton, composed of actin filaments, microtubules, and intermediate filaments, is vital for maintaining cellular structure, intracellular transport, and signalling. G-protein coupled receptors, widely expressed in neuroglial cells, play critical roles in neuroinflammation, synaptic pruning, and cytoskeletal dynamics in neurodegenerative diseases. Extracellular Tau species interact with GPCRs, particularly in microglia and astrocytes, triggering neuroinflammatory responses and cytoskeletal remodelling. Key kinases such as Glycogen Synthase Kinase-3β and C
Contradicts
Glial Cells in the Early Stages of Neurodegeneration: Pathogenesis and Therapeutic Targets.
Abstract
Astrocytes and microglia constitute nearly half of all central nervous system cells and are indispensable for its proper function. Both exhibit striking morphological and functional heterogeneity, adopting either neuroprotective (A2, M2) or proinflammatory (A1, M1) phenotypes in response to cytokines, pathogen-associated molecular patterns (PAMPs)/damage-associated molecular patterns (DAMPs), toll-like receptor 4 (TLR4) activation, and NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome signaling. Crucially, many of these phenotypic transitions arise during the earliest stages of neurodegeneration, when glial dysfunction precedes overt neuronal loss and may act as a primary driver of disease onset. This review critically examines glial-centered hypotheses of neurodegeneration, with emphasis on their roles in early disease phases: (i) microglial polarization from an M2 neuroprotective state to an M1 proinflammatory state; (ii) NLRP3 inflammasome assembly via P2X puri
Contradicts
CX3CR1: a potential microglia-specific PET imaging target in Alzheimer's and Parkinson's diseases.
Abstract
Microglia are the resident immune cells of the central nervous system (CNS), playing a crucial role in maintaining brain homeostasis and mediating neuroimmune responses. The chemokine receptor CX3CR1, predominantly expressed on microglia, regulates microglial function via interactions with its neuronal ligand CX3CL1. The CX3CR1-CX3CL1 signaling exhibits complex, context-dependent roles in neurodegenerative diseases. In Alzheimer's disease (AD) and Parkinson's disease (PD) animal models, CX3CR1 deficiency shows paradoxical outcomes, attenuating or exacerbating amyloid-β (Aβ) and tau pathologies in AD, while consistently worsening α-synuclein-induced neurodegeneration in PD. Although CX3CR1 emerges as a promising therapeutic and diagnostic target, its complex role in microglial dynamics remains incompletely understood. Positron emission tomography (PET) imaging provides a powerful, noninvasive method for investigating biological processes in vivo. There is an urgent need to develop and v
📖 Linked Papers (30)Export BibTeX ↗
Glial Cells in the Early Stages of Neurodegeneration: Pathogenesis and Therapeutic Targets.
International journal of molecular sciences (2025) · PubMed:41465422 ↗
5 figures
Figure 1
Hypothesis of microglial polarization from the M2 to M1 phenotype and NLRP3 inflammasome activation. Panel ( A ) In the APP/PS1 mouse model of Alzheimer’s disea...
Figure 2
Hypothesis of crosstalk among microglia, astrocytes, and neurons. Panel schematic on the ( right ). An M1 polarized microglial cell releases proinflammatory med...
Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases.
J Inflamm Res (2022) · PubMed:35642214 ↗
2 figures
Figures
Figures available at source paper (no open-access XML found).
Figures
Figures available at source paper (no open-access XML found).
CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases.
Pharmacol Ther (2022) · PubMed:34492237 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Microglia in neurodegeneration.
Nat Neurosci (2018) · PubMed:30258234 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
CX3CR1-T280M polymorphism and end-stage renal disease development in chronic kidney disease.
Scientific reports (2026) · PubMed:41932952 ↗
No figures
[Corrigendum] Influence of aspirin on the CX3CL1/CX3CR1 signaling pathway in acute pulmonary embolism.
Int J Mol Med (2026) · PubMed:41930567 ↗
No figures
Constitutive expression of CX3CR1-BAC-Cre introduces minimal off-target effects in microglia.
Biochemical and biophysical research communications (2026) · PubMed:41924777 ↗
No figures
Microglia-glioblastoma crosstalk mediates glioblastoma invasion at the far infiltration zone.
Immunity (2026) · PubMed:41923645 ↗
No figures
Identification of suicide brain transcriptomic signatures using meta-analysis of multiple cohorts.
Translational psychiatry (2026) · PubMed:41916959 ↗
No figures
G-protein coupled receptor chemokine CX3CR1 influences extracellular Tau internalization in Alzheimer's disease.
Advances in protein chemistry and structural biology (2026) · PubMed:41904008 ↗
No figures
Conserved ductular reaction mechanisms in biliary atresia and PSC derived from single-cell and spatial transcriptomics.
Cellular and molecular gastroenterology and hepatology (2026) · PubMed:41903685 ↗
No figures
📙 Related Wiki Pages (15)
CX3CR1 — CX3C Chemokine Receptor 1geneSynaptic Biomarkers in NeurodegenerationbiomarkerDNA Methylation Biomarkers in NeurodegenbiomarkerExosomal miR-155 in NeurodegenerationbiomarkerNeuroimaging Biomarkers for NeurodegenerbiomarkerMetabolomic Biomarkers in NeurodegeneratbiomarkerGlutamate - Excitotoxicity and NeurodegebiomarkerCSF Neurofilament Light Chain (NfL) in NbiomarkerBlood-Based Biomarkers for NeurodegenerabiomarkerExosomal Biomarkers in NeurodegenerationbiomarkerLiquid Biopsy in NeurodegenerationbiomarkerIL-6 (Interleukin-6) in NeurodegeneratiobiomarkerMDS 2026 — Fluid Biomarker Advances in NeventCell-Free DNA Biomarkers in NeurodegenerbiomarkerAdrenal Chromaffin Cells in Neurodegenercell
🏥 Translation
🔮 Predicted Protein Structure — CX3CR1
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for CX3CR1 from GTEx v10.
💉 Clinical Trials (4)Relevance: 13%
2
Active
Active
2
Completed
Completed
0
Total Enrolled
Total Enrolled
Phase II
Highest Phase
Highest Phase
Recruiting·NCT03999515
Completed·NCT04777396
Recruiting·NCT04592874
Completed·NCT03943264
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CX3CR1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
2.3 years
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.7%
Volatility
Medium
0.0404
Events (7d)
5
Price History
▼33.1%💾 Resource Usage
LLM Tokens
17,956
$0.1077
Total Cost
$0.1077
🧭 Related
🕸 Knowledge Subgraph (89 edges)Showing top 50 of 89 edges by weightCentered on CX3CR1
Top relations:co discussed (38)co associated with (13)associated with (11)implicated in (7)regulates (4)participates in (4)
🔍 Show all 50 edges across 14 relations
associated with (11)
causes (2)
co associated with (12)
contributes to (1)
fuels (1)
implicated in (6)
h-1fe4ba9b→neurodegenerationh-f99ce4ca→neurodegenerationh-ba3a948a→neurodegenerationh-044ee057→neurodegenerationh-513a633f→neurodegeneration
▸ Show 1 more
maintains (1)
participates in (2)
rate limits (1)
regulates (4)
suppresses (1)
🗺️ KG Entities (61)
ANXA1Alzheimer's_diseaseC1QC1QACOGNITIVE DECLINECX3CR1Complement activationComplement pathwayCx3Cl1DAMPsDAP12Fractalkine receptor / microglia-neuroGSDMDHK2Metabolic modulatorsMetforminMicroglial activation / TREM2 signalinNLRP3Neuronal survivalP2RY12P38PI3KPKM2RapamycinSOD1SYNAPTIC PRUNINGSynaptic TaggingSynaptic function / plasticityTREM2TREM2 activationTREM2-DAP12 microglial signalingamyloiddebris clearanceeat_me_signalsfractalkine_signalingglycolysish-044ee057h-1fe4ba9bh-38292315h-513a633fh-782b40b1h-ba3a948ah-f99ce4cainflammationmicrogliamicroglial metabolic statemicroglial oxidative metabolismmicroglial pruning capacitymicroglial_activationmicroglial_phagocytosismicroglial_process_motilitymicroglial_surveillanceneurodegenerationneuroinflammationneuroprotectionphosphatidylserine_maskingprocessedsess_sda-2026-04-01-gap-v2-691b42f1synapse losssynaptic pruningtrophic support
🔗 Dependency Graph (1 upstream, 4 downstream)
🧪 Adjacent Hypotheses10 siblings from the same analysis
Purinergic P2Y12 Inverse Agonist Therapy
0.70P2RY12 · neurodegeneration · debated
Complement C1q Mimetic Decoy Therapy
0.69C1QA · neurodegeneration · debated
TREM2 Conformational Stabilizers for Synaptic Discrimination
0.69TREM2 · neurodegeneration · debated
Metabolic Reprogramming via Microglial Glycolysis Inhibition
0.67HK2 · neurodegeneration · debated
Optogenetic Microglial Deactivation via Engineered Inhibitory Opsins
0.66CX3CR1 · neurodegeneration · debated
Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
0.62ANXA1 · neurodegeneration · debated
Fractalkine Axis Restoration for Neuroprotective Signaling
0.00CX3CL1 · proposed
Metabolic Reprogramming of Pruning Microglia
0.00PKM2 · proposed
Engineered Anti-Complement Synaptic Tags
0.00C3 · proposed
Synaptic Activity-Dependent Protection System
0.00ARC · proposed
🗣 Debate PerspectivesGap Analysis | 4 rounds | 2026-04-01
🔮 Predictions
🔎 Predictions vs Observations5 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| sufficient vs C1q-deficient AD mice 2. Measure systemic immune function (bacterial clearance, autoantibody formation) during chronic decoy treatment 3. Examine whether decoys prevent beneficial C1q fu | Confirmatory evidence for hypothesis | — no observation — | pending | 0.60 |
| response curves for both anti-inflammatory markers and synaptic preservation 3. Compare effects in microglia-specific vs pan-cellular CX3CR1 modulation | Confirmatory evidence for hypothesis | — no observation — | pending | 0.60 |
| penetrant P2Y12 inverse agonists | Confirmatory evidence for hypothesis | — no observation — | pending | 0.60 |
| specific metabolic inhibition using cell-type-specific delivery systems 2. Measure microglial viability and essential functions during forced metabolic reprogramming 3. Compare effects in different br | Confirmatory evidence for hypothesis | — no observation — | pending | 0.60 |
| term opsin expression in neuroinflammatory conditions 3. Compare localized vs distributed optogenetic control for preventing synaptic loss 4. Assess whether benefits persist when light stimulation i | Confirmatory evidence for hypothesis | — no observation — | pending | 0.60 |
🔮 Falsifiable Predictions (5)
pendingconf 60%
sufficient vs C1q-deficient AD mice
2. Measure systemic immune function (bacterial clearance, autoantibody formation) during chronic decoy treatment
3. Examine whether decoys prevent beneficial C1q functions like amyloid phagocytosis
Predicted outcome: Confirmatory evidence for hypothesis
Falsification: Failure of: sufficient vs C1q-deficient AD mice
2. Measure systemic immune function (bacterial clearance, autoantibody formation) during chronic decoy treatment
3. Examine whether decoys prevent benef
pendingconf 60%
response curves for both anti-inflammatory markers and synaptic preservation
3. Compare effects in microglia-specific vs pan-cellular CX3CR1 modulation
Predicted outcome: Confirmatory evidence for hypothesis
Falsification: Failure of: response curves for both anti-inflammatory markers and synaptic preservation
3. Compare effects in microglia-specific vs pan-cellular CX3CR1 modulation
pendingconf 60%
penetrant P2Y12 inverse agonists
Predicted outcome: Confirmatory evidence for hypothesis
Falsification: Failure of: penetrant P2Y12 inverse agonists
pendingconf 60%
specific metabolic inhibition using cell-type-specific delivery systems
2. Measure microglial viability and essential functions during forced metabolic reprogramming
3. Compare effects in different brain regions with varying baseline metabolic demands
Predicted outcome: Confirmatory evidence for hypothesis
Falsification: Failure of: specific metabolic inhibition using cell-type-specific delivery systems
2. Measure microglial viability and essential functions during forced metabolic reprogramming
3. Compare effects in
pendingconf 60%
term opsin expression in neuroinflammatory conditions
3. Compare localized vs distributed optogenetic control for preventing synaptic loss
4. Assess whether benefits persist when light stimulation is discontinued
Predicted outcome: Confirmatory evidence for hypothesis
Falsification: Failure of: term opsin expression in neuroinflammatory conditions
3. Compare localized vs distributed optogenetic control for preventing synaptic loss
4. Assess whether benefits persist when light s
📖 References (11)
- Visual representations by cortical somatostatin inhibitory neurons--selective but with weak and delayed responses.["Ma W" et al.. The Journal of neuroscience : the official journal of the Society for Neuroscience (2010)
- Specific profile of tau isoforms in argyrophylic grain disease.["R\u00e1bano A" et al.. Journal of experimental neuroscience (2013)
- Synaptic pruning by microglia is necessary for normal brain development.["Paolicelli R" et al.. Science (New York, N.Y.) (2011)
- The Role of Functional Imaging in Radiotherapy Planning and Management for Gynecologic Malignancies.["Ma D" et al.. PET clinics (2011)
- Ni Foam-Ni["Wang X" et al.. Chemistry (Weinheim an der Bergstrasse, Germany) (2017)
- HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants.["Nguyen A" et al.. Cell reports (2018)
- Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases.Wang M et al.. J Inflamm Res (2022)
- Microglia in neurodegeneration.Hickman S et al.. Nat Neurosci (2018)
- Constitutive expression of CX3CR1-BAC-Cre introduces minimal off-target effects in microglia.["Mroue-Ruiz F" et al.. bioRxiv : the preprint server for biology (2024)
- How neuroinflammation contributes to neurodegeneration.Ransohoff RM. Science (2016)
- CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases.Subbarayan MS et al.. Pharmacol Ther (2022)
Related Entities
▸Metadata
| status | proposed |
| _schema_version | 1 |
| hypothesis_type | None |
📊 Evidence Profile
Foundational
Evidence Balance
+0%
Certainty
100%
Debates
2
Incoming
3680
Outgoing
2056
0 supporting
0 contradicting
2 neutral
🌍 Provenance Graph
8 nodes, 14 edges
derives from (14)
hypothesis-h-ba3a948a→analysis-SDA-2026-04-01-gap-v2analysis-SDA-2026-04-01-gap-v2→hypothesis-h-f99ce4cahypothesis-h-f99ce4ca→analysis-SDA-2026-04-01-gap-v2analysis-SDA-2026-04-01-gap-v2→hypothesis-h-1fe4ba9bhypothesis-h-1fe4ba9b→analysis-SDA-2026-04-01-gap-v2
▸ Show 9 more
analysis-SDA-2026-04-01-gap-v2→hypothesis-h-ba3a948aanalysis-SDA-2026-04-01-gap-v2→hypothesis-h-38292315hypothesis-h-38292315→analysis-SDA-2026-04-01-gap-v2analysis-SDA-2026-04-01-gap-v2→hypothesis-h-513a633fhypothesis-h-513a633f→analysis-SDA-2026-04-01-gap-v2analysis-SDA-2026-04-01-gap-v2→hypothesis-h-044ee057hypothesis-h-044ee057→analysis-SDA-2026-04-01-gap-v2analysis-SDA-2026-04-01-gap-v2→hypothesis-h-782b40b1hypothesis-h-782b40b1→analysis-SDA-2026-04-01-gap-v2
🗣 Debate History2 sessions
gap_analysisWhat are the mechanisms underlying synaptic pruning by microglia in early ad?r4q=0.952026-04-01
gap_analysisWhat are the mechanisms underlying synaptic pruning by microglia in early ad?r4q=0.952026-04-01+0.000
This artifact has no version history yet.
Linked Artifacts (5724)
🧬 Related Hypotheses — same target / disease (8)
Optogenetic Microglial Deactivation via Engineered Inhibitory Opsins
Score: 0.655 · Target: CX3CR1 · neurodegeneration
CX3CR1 Promoter Methylation Disrupts Neuron-Microglia Cross-Talk
Score: 0.649 · Target: CX3CR1 · developmental-neurobiology
CX3CR1 Agonism Enhances Microglial Phagocytosis of Extracellular Tau Seeds, Preventing Tem
Score: 0.630 · Target: CX3CR1 · neurodegeneration
Stratified falsifiers should govern Microglial Priming as Upstream Causal Node Across AD,
Score: 0.591 · Target: CX3CR1 · neurodegeneration
CX3CR1 PET with Nano-bodies for Microglial Surveillance State Mapping
Score: 0.477 · Target: CX3CR1 · biomarkers
Spinal Cord Microglia Activation State Convergence
Score: 0.455 · Target: CX3CR1 · neuroinflammation
Microglia-Mediated Synaptic Pruning Modulation to Optimize Functional Connectome Efficienc
Score: 0.380 · Target: CX3CR1 · connectomics
CX3CR1-Targeted Regulatory T Cell Homing
Score: 0.000 · Target: CX3CR1 · —
Reference URLs
Embed this artifact
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
HTML iframe
<iframe src="http://scidex.ai/artifact/hypothesis-h-ba3a948a?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
Markdown link
[Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators](http://scidex.ai/artifact/hypothesis-h-ba3a948a)
Direct URL
http://scidex.ai/artifact/hypothesis-h-ba3a948a
Preview
🔄 Adjacent Artifacts
Recommended based on your interests
💬 Discussion
Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.